The FDA recorded a supplement to an abbreviated new drug application for tigecycline from a generic manufacturer. A supplement to a generic application is an administrative step, typically covering manufacturing or labelling, and it signals continued generic availability rather than any change in how the drug should be used.
Tigecycline remains a reserve agent, used mainly for complicated infections when first-line options fail, and it carries a long-standing caution about higher mortality seen in pooled trials when used outside its approved indications. Nothing in a generic supplement changes that; it is noted here only because the regulatory sweep flagged it.
- The FDA logged a generic manufacturer's supplement for tigecycline.
- A supplement to a generic application is administrative, not a new approval or indication.
- Tigecycline stays a reserve antibiotic for complicated infections after first-line failure.
- Its established mortality caution outside approved uses is unchanged.
Why it matters
Generic supply of reserve antibiotics matters for access in high-resistance settings, even when the regulatory step itself is routine.
Don't overread it
This is an administrative generic supplement, not a safety communication, new indication or efficacy finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free